Safety of biologic therapy - Results from the German biologics register RABBIT;Sicherheit unter Biologika - Ergebnisse aus dem deutschen Biologika-Register RABBIT

Deutsche Medizinische Wochenschrift

Volumn 139, Issue 37, 2014, Pages 1817-1820

  Strangfeld, A ^a   Zink, A ^a,b  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biologics; drug safety; infections; malignancies; mortality; rheumatoid arthritis

Indexed keywords

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COMORBIDITY; GLUCOCORTICOIDS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; NEOPLASMS; OPPORTUNISTIC INFECTIONS; REGISTRIES; RISK; STROKE; SURVIVAL ANALYSIS;

EID: 84906875627     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0034-1370252     Document Type: Review

References (19)

1. Askling J., Fored C. M., Brandt L. et al. Time-dependent increase in risk of hospitalisation with infection among swedish ra-patients treated with tnf-antagonists. Ann Rheum Dis: 2007; 66 1339 1344
2. Avina-Zubieta J. A., Choi H. K., Sadatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum: 2008; 59 1690 1697
3. Dixon W. G., Symmons D. P., Lunt M. et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum: 2007; 56 2896 2904
4. Dixon W. G., Watson K. D., Lunt M. et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken): 2010; 62 755 763
5. Dreyer L., Mellemkjaer L., Andersen A. R. et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis: 2012; 72 79 82
6. John H., Kitas G., Toms T. et al. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol: 2009; 23 71 82
7. Listing J., Kekow J., Manger B. et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis: 2013; Nov 29 [Epub ahead of print]
8. Listing J., Strangfeld A., Kary S. et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum: 2005; 52 3403 3412
9. Listing J., Strangfeld A., Kekow J. et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum: 2008; 58 667 677
10. Lunt M., Watson K. D., Dixon W. G. et al. No evidence of association between anti-TNF treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum: 2010; 62 3145 53
11. Strangfeld A., Hierse F., Rau R. et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther: 2010; 12 R5
12. Strangfeld A., Richter A., Meissner Y. et al. High risk of developing fatal infections in RA patients with congestive heart failure. Ann Rheum Dis: 2014; 73 02 124
13. Maradit-Kremers H., Nicola P. J., Crowson C. S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum: 2005; 52 722 732
14. Meissner Y., Kühl-Habich D., Kekow J. et al. Acute myocardial infarction is driven by chronic inflammation, irrespective of the kind of treatment - Data of the German biologics register RABBIT. Ann Rheum Diss: 2013; 72 03 744
15. Mercer L. K., Green A. C., Galloway J. B. et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis: 2012; 71 869 874
16. Naz S. M., Symmons D. P. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol: 2007; 21 871 883
17. Raaschou P., Simard J. F., Holmqvist M. et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ: 2013; 346 f1939
18. Strangfeld A., Eveslage M., Schneider M. et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis: 2011; 70 1914 1920
19. Zink A., Manger B., Kaufmann J. et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis: 2013; 10.1136/annrheumdis-2013- 203341